FDA instructs Amgen to pull Enbrel ads

The FDA ordered Amgen to pull its television ads for Enbrel, indicated for psoriasis, on grounds the advertisement did not disclose risks or mention the drug was indicated only for "chronic moderate to severe plaque psoriasis," and not milder forms. The agency also told the company its ad overstated Enbrel's effectiveness. An Amgen spokeswoman said the ad has been pulled and the company is reviewing the letter.